Vinge has advised CELLINK AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm Main Market, with an estimated market capitalisation of approximately SEK 4.1 billion. The prospectus was published on 15 April 2020 and the trading on Nasdaq Stockholm commenced on 20 April 2020.
CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. CELLINK focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing. The target is to develop and commercialise cell culture technologies, enabling researchers to 3D-print human organs and tissues for pharmaceutical and cosmetic applications.
Vinge’s team has primarily consisted of Anders Strid, Wibeke Sorling, Edin Agic and Johanna Hamrefält (Capital Markets and Public M&A) as well as Victor Ericsson and Emelie Svanberg (Corporate Tax).